ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

VER Vernalis

6.17
0.00 (0.00%)
Last Updated: 01:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Vernalis LSE:VER London Ordinary Share GB00B3Y5L754 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 6.17 - 0.00 01:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Vernalis Share Discussion Threads

Showing 3226 to 3249 of 3850 messages
Chat Pages: Latest  130  129  128  127  126  125  124  123  122  121  120  119  Older
DateSubjectAuthorDiscuss
03/11/2016
00:05
12 to 15 months from now if the earlier announcement pans out.Getting FDA clearance for a new site and production quality won't be easy. I don't know why they didn't come to some arrangement with the administrator for the previous plant in Ireland.
fhmktg
02/11/2016
14:46
fhmktg ...the trade at 11.48 and 11.49 look like a roll over...when are they going to inform us about the supply lines and if another producer has been found .
twodegrees
02/11/2016
13:43
Interesting cluster of buys today!
fhmktg
02/11/2016
05:15
Do you guys realize that not all drugs that get FDA approval go on to sell in a way that makes the parent company any lolly ?
buywell3
14/10/2016
20:52
fhmktg thank you...looks interesting with a pipeline of work on the go.
twodegrees
14/10/2016
00:05
www.fiscalstandard.com/2016/10/13 and the search for vernalis
fhmktg
14/10/2016
00:01
Just google Cantor Fitzgerald and Vernalis
fhmktg
13/10/2016
16:30
fhmktg...do you have a link to the cantor target
twodegrees
13/10/2016
16:23
not that is a bloomin good target...what do they know that they are not sharing with us...
twodegrees
13/10/2016
15:45
Ah! It was Cantor Fitzgerald setting a target price of 101p.
fhmktg
13/10/2016
08:52
Somebody is building their stake this morning!
fhmktg
12/10/2016
14:39
fhmtg thanks for that...I was thinking that financial messages had changed codes or something.... let us hope that a new supplier is named soon.
twodegrees
12/10/2016
13:11
oh, re-establishing, now that makes sense :)
yes could do with more news on that

bountyhunter
11/10/2016
23:22
Sorry for the spelling; I wouldn't have thought they would go ahead promoting the product to the market unless they had some candidates in line to provide reliable manufacture of the Product before their limited supply runs out.Maybe I'm missing something?
fhmktg
11/10/2016
20:50
fhmktg I had followed that but what do you mean by confident about rare-establishing a supplier
twodegrees
11/10/2016
17:36
See news release in May
fhmktg
11/10/2016
17:34
The Irish supplier of the formulation for Moxatag has gone into administration.
fhmktg
11/10/2016
16:57
fhmktg care to explain please...note we have hit another new low.
twodegrees
11/10/2016
16:40
Must be confident about rare-establishing a supplier!
fhmktg
02/10/2016
12:17
Review listed on the Vectura board lists Verona RPL554 as a potential new type of treatment for athsma and related conditions.This is from VER stable.
fhmktg
29/9/2016
15:07
Another 'bolt on' product would come in handy.
fhmktg
29/9/2016
15:06
The PowerPoint presentation gives a good detailed outline of Tuzistra and its market reaction and strategy.Good learning for the introduction of the next product for season 17/18. Keep the faith!
fhmktg
29/9/2016
14:51
ok, the current situation regarding that is not entirely clear from today's RNS, I hope you're wrong as well as we would probably both benefit!
bountyhunter
29/9/2016
11:18
How do you work that out from the following statements in today's RNS?

-- "Focused US primary care sales force fully recruited, trained and deployed to the field
-- US rights to Moxatag(R) , the only US approved once-a-day formulation of amoxicillin, acquired in October 2015, validating the Company's ability to expand its US commercial portfolio

...Re-launch Moxatag(R) in the US market through our focused US primary care sales force (H2 2016 calendar year)

...We will leverage this investment and our US commercial infrastructure to launch the once-a-day antibiotic, Moxatag(R) in the second half of 2016.

...Our cash position was bolstered following the recent equity raise to continue the promotional investment in Tuzistra(R) XR as well as launch Moxatag(R) and our additional products, CCP-07 and CCP-08 in the near term. We remain very excited about the growth potential of the business."



There is still just over 3 months to go to the end of the H2 2016 calendar year with autumn/winter just starting.

bountyhunter
Chat Pages: Latest  130  129  128  127  126  125  124  123  122  121  120  119  Older

Your Recent History

Delayed Upgrade Clock